Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Our Products
MouseAtlas
iPSC Cell Lines
Knockout Cell Lines
Tumor Cell Lines
Adeno-associated Virus (AAV) Standard Capsid
Featured Catalog
Humanized Mouse Models
HUGO-GT™
HUGO-Ab™
Humanized Target Gene Models
Humanized Immune System Mouse Models
Tool Mice
Cre Mouse Lines
Disease Models
Autoimmune Disease Models
Ophthalmic Disease Models
Immunodeficient Mouse Models
Metabolic Disease Models
Neurological Disease Models
Oncology & Immuno-oncology Models
Services
Model Generation Techniques
Turboknockoutᵀᴹ Gene Targeting
Cre-ESCs Gene Editing
Targeted Gene Editing
Genetically Engineered Animals
Knockin Mice
Knockin Rats
Knockout Mice
Knockout Rats
Transgenic Mice
Transgenic Rats
Transgenic Model Generation
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Adenovirus Packaging
Lentivirus Packaging
Custom Cell Line Services
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Overexpression Cell Lines
Point Mutation Cell Lines
Breeding & Supporting Services
BAC Modification
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
Drug Discovery and Development
Antibody Discovery Platform
HUGO-Ab™
HUGO-Mab™
HUGO-Light™
HUGO-Nano™
HUGO-Ab-eKO™
Therapeutic Area
Neurology
Alzheimer's Disease (AD)
Parkinson's Disease (PD)
Huntington's Disease (HD)
Blood Brain Barrier (BBB)
Metabolic & Cardiovascular
Obesity
Ophthalmology
Glaucoma
Age-Related Macular Degeneration (AMD)
Oncology
PBMC Humanized Mouse Model
Human Immune System (HIS) Mouse Model
Immunology & Inflammation
Asthma
Innovative Drug R&D
Therapeutic Antibody Drugs
Monoclonal Antibodies (mAb)
Bispecific Antibodies (BsAb)
ADC/AOC
AI-Powered AAV Discovery
Cell Immunotherapy
Gene Therapy
Oligonucleotide Therapy
Fully Human Antibody Library
Neurology Antibodies
Metabolic & Cardiovascular Antibodies
Ophthalmology Antibodies
Oncology Antibodies
Immunology & Inflammation Antibodies
Resources
News
Blogs & Insight
Promotion
Events & Webinars
Databases
AbSeek
Rare Disease Data Center
Cell iGeneEditor™ System
Citations
Resource Vault
OriCell
About Us
Animal Health & Welfare
Corporate Overview
Facility Overview
Our Team
Our Partners
Careers
Health Reports
Contact Us
Login
HomeMouseAtlas
C57BL/6JCya-Tlr6em1/Cya
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Catalog Type
Product Name
Main Area of Research
How did you hear about us?
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.

C57BL/6JCya-Tlr6em1/Cya

Common Name
Tlr6-KO
Product ID
S-KO-17564
Backgroud
C57BL/6JCya
Strain ID
KOCMP-21899-Tlr6-B6J-VA
Status
Research and Development
When using this mouse strain in a publication, please cite “Tlr6-KO Mouse (Catalog S-KO-17564) were purchased from Cyagen.”
KO Models
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
KO Models
Basic Information
Strain Name
Tlr6-KO
Strain ID
KOCMP-21899-Tlr6-B6J-VA
Gene Name
Tlr6
Product ID
S-KO-17564
Gene Alias
--
Background
C57BL/6JCya
Gene Full Name
toll-like receptor 6
Modification
Conventional knockout
NCBI ID
21899 (Mouse)
Phenotype
MGI:1341296
Chromosome
Chr 5 (Mouse)
Application
--
Datasheet
Click here to download >>
More
Rare Disease Data Center >>
Strain Description
Ensembl Transcript ID
ENSMUST00000239485
NCBI Transcript ID
NM_011604
Target Region
Exon 2
Size of Effective Region
~2.7 kb
Overview of Gene Research
Tlr6, a member of the Toll-like receptor family, is a type-I transmembrane receptor with an extracellular leucine-rich repeat (LRR) domain and a cytoplasmic Toll/IL-1 receptor-like region [6]. It plays a crucial role in the innate immune response by recognizing conserved microbial products, such as peptidoglycan from Gram-positive bacteria. TLR6 often forms heterodimers with TLR2 to activate the signaling cascade, leading to the activation of multiple inflammatory genes and thus regulating both innate and adaptive immunity [3].

In terms of disease-related findings, the TLR2/TLR6 ligand FSL-1 was shown to mitigate radiation-induced hematopoietic injury in mice and non-human primates, promoting hematopoietic progenitor cell proliferation and red blood cell development [1]. High TLR6 expression status in locally advanced thoracic esophageal squamous cell carcinoma patients predicted a more favorable prognosis after esophagectomy, and peptidoglycan (recognized by TLR6) inhibited the cell proliferation activity of esophageal squamous cell carcinoma lines [2]. In sepsis-induced ARDS, miR-34a-5p may promote TLR6 to heighten inflammation [4]. Also, sustained exposure to Helicobacter pylori desensitized TLR6, inducing immune tolerance, and restoration of TLR6 reduced H. pylori colonization in gerbils [5].

In conclusion, Tlr6 is essential for innate immunity and has significant implications in various disease conditions. Studies using animal models, like the non-human primates and gerbils in the above-mentioned research, have revealed its role in radiation-induced hematopoietic injury, cancer prognosis, and infectious disease-related immune responses. Understanding Tlr6 function provides potential therapeutic targets for these diseases.

References:
1. Brickey, W June, Caudell, David L, Macintyre, Andrew N, Cline, J Mark, Ting, Jenny P Y. 2023. The TLR2/TLR6 ligand FSL-1 mitigates radiation-induced hematopoietic injury in mice and nonhuman primates. In Proceedings of the National Academy of Sciences of the United States of America, 120, e2122178120. doi:10.1073/pnas.2122178120. https://pubmed.ncbi.nlm.nih.gov/38051771/
2. Sato, Yusuke, Wakita, Akiyuki, Maeda, Eri, Nomura, Kyoko, Minamiya, Yoshihiro. 2023. High TLR6 Expression Status Predicts a More Favorable Prognosis after Esophagectomy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma. In Current oncology (Toronto, Ont.), 30, 4724-4735. doi:10.3390/curroncol30050356. https://pubmed.ncbi.nlm.nih.gov/37232814/
3. Noreen, Mamoona, Arshad, Muhammad. . Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. In Immunologic research, 62, 234-52. doi:10.1007/s12026-015-8640-6. https://pubmed.ncbi.nlm.nih.gov/25784622/
4. Khan, Mohd Junaid, Singh, Prithvi, Jha, Prakash, Singh, Indrakant Kumar, Syed, Mansoor Ali. 2023. Investigating the link between miR-34a-5p and TLR6 signaling in sepsis-induced ARDS. In 3 Biotech, 13, 282. doi:10.1007/s13205-023-03700-1. https://pubmed.ncbi.nlm.nih.gov/37496978/
5. Zhang, Xiulin, He, Yang, Zhang, Xiaolu, Chen, Zhenwen, Li, Changlong. 2024. Sustained exposure to Helicobacter pylori induces immune tolerance by desensitizing TLR6. In Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 27, 324-342. doi:10.1007/s10120-023-01461-7. https://pubmed.ncbi.nlm.nih.gov/38310631/
6. Takeuchi, O, Kawai, T, Sanjo, H, Takeda, K, Akira, S. . TLR6: A novel member of an expanding toll-like receptor family. In Gene, 231, 59-65. doi:. https://pubmed.ncbi.nlm.nih.gov/10231569/
Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Inquiry Details
Main Area of Research
Service(s) of Interest
Gene of Interest
Project Details
How did you hear about us?
Contact Information
Full Name
Email
Phone Number
+
-
Organization
Job Role
Country
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our  Privacy Policy  for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0336
Email:
inquiry@cyagen.com
Services
HUGO-GT™HUGO-Ab™iPSC Cell LinesAdeno-associated Virus (AAV) Standard Capsid
Drug R&D
NeurologyMetabolicOphthalmologyOncology
About Us
Animal Health & WelfareCorporate OverviewOur TeamHealth Reports
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Global Antibody Drug Industry Development BlueBook (Frost & Sullivan)
Key Insights
The industry is undergoing a rapid transformation driven by next-generation modalities, globalized markets, and upstream technological innovations.
  • Market Structural Shift: Monoclonal antibodies drive steady growth, but ADCs and bispecifics are rapidly accelerating, reshaping the market with higher-value innovations.
  • Chinese Market Globalization: China is actively expanding globally, evidenced by a surge in high-value cross-border license-out deals.
  • Technology-Driven Efficiency: Advanced discovery engines—exemplified by Cyagen's HUGO-Ab platform and AI algorithms—are streamlining candidate screening, optimizing molecular design, and localizing the upstream supply chain.
  • Oncology-Focused Innovation: R&D pipelines remain heavily concentrated on high-incidence malignancies like non-small cell lung cancer, utilizing complex modalities to combat clinical resistance.
Now Available for Download
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest
Main Area of Research